(b) (4)

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

10 mg

For Intragluteal Injection

300017779 US

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

10 mg

For Intragluteal Injection

Each vial delivers:
octreotide acetate ..... 11.2 mg*
*equivalent to 10 mg octreotide base
Inactive ingredients:
D,L-lactic and glycolic acids copolymer ..... 188.8 mg
mannitol ..... 41.0 mg

Each diluent syringe contains:
Carboxymethylcellulose sodium ..... 14 mg
mannitol ..... 12 mg
poloxamer 188 ..... 4 mg
water for injection ..... 2 mL

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

Product of Switzerland.

Rx only

For Intragluteal Injection

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

10

Sandostatin® LAR Depot
Vials are manufactured by:
Sandoz GmbH,
Schaftenau, Austria
(Subsidiary of Novartis Pharma AG,
Basel, Switzerland)

Diluent syringes are manufactured by:
Abbott Biologicals B.V.
Olst, The Netherlands

Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

300017779 US

NOVARTIS

For Intragluteal Injection

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

10 mg

NOVARTIS

Rx only

10

(b) (4)

95 x 36 x 219

N 3 0078-0811-81 1

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

10 mg

For Intragluteal Injection

If you have any questions about preparation and/or administration, please call 1-888-NOW-NOVA (1-888-669-6682).

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

300017779 US

Contents:
- One vial containing Sandostatin® LAR Depot
- One prefilled syringe containing diluent solution for reconstitution
- One vial adapter for drug product reconstitution
- One 1.5" x 19 gauge safety injection needle

10 mg
For Intragluteal Injection
NDC 0078-0811-81

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

10

NOVARTIS

Rx only

(b) (4)

473 58
3086A1

GTIN
EXP
LOT
SN

(b) (4)

Sandostatin® LAR Depot

(octreotide acetate) for injectable suspension, for gluteal intramuscular use

20 mg

NOVARTIS

For Intragluteal Injection

Contents:
- One vial containing Sandostatin® LAR Depot
- One prefilled syringe containing diluent solution for reconstitution
- One vial adapter for drug product reconstitution
- One 1.5" x 19 gauge safety injection needle

20 mg
For Intragluteal Injection
NDC 0078-0818-81

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

Rx only NOVARTIS

(b) (4)

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg
for gluteal intramuscular use

For Intragluteal Injection

3000178 00 US

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg
for gluteal intramuscular use

For Intragluteal Injection

If you have any questions about preparation and/or administration, please call 1-888-NOW-NOVA (1-888-669-6682).

0078-0818-81 0

95 x 36 x 219

GTIN
EXP
LOT
SN

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg
for gluteal intramuscular use

For Intragluteal Injection

Each vial delivers:
octreotide acetate ..... 22.4 mg*
*equivalent to 20 mg octreotide base

inactive ingredients:
D,L-lactic and glycolic acids copolymer ..... 377.6 mg
mannitol ..... 81.9 mg

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

Product of Switzerland

Rx only

Each diluent syringe contains:
Carboxymethylcellulose sodium ..... 14 mg
mannitol ..... 12 mg
poloxamer 188 ..... 4 mg
water for injection ..... 2 mL

For Intragluteal Injection

20

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, for gluteal intramuscular use

Sandostatin® LAR Depot Vials are manufactured by:
Sandoz GmbH,
Schaftenau, Austria
(Subsidiary of Novartis Pharma AG,
Basel, Switzerland)

Diluent syringes are manufactured by:
Abbott Biologicals B.V.
Olst, The Netherlands

Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

30001 7800 US

20

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg
for gluteal intramuscular use

For Intragluteal Injection

47358
30868A1

(b) (4)

(b) (4)

95 x 36 x 219

GTIN
LOT
EXP
SN

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 30 mg
for gluteal intramuscular use

For Intragluteal Injection

NDC 0078-0825-81

If you have any questions about preparation and/or administration, please call 1-888-NOW-NOVA (1-888-669-6682).

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

300017795 US

Contents:
- One vial containing Sandostatin® LAR Depot
- One prefilled syringe containing diluent solution for reconstitution
- One vial adapter for drug product reconstitution
- One 1.5" x 19 gauge safety injection needle

30 mg
For Intragluteal Injection
NDC 0078-0825-81

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use

30

Rx only

NOVARTIS

(b) (4)

Each vial delivers:
octreotide acetate ..... 33.6 mg*
*equivalent to 30 mg octreotide base
Inactive ingredients:
D,L-lactic and glycolic acids copolymer ..... 566.4 mg
mannitol ..... 122.9 mg

Each diluent syringe contains:
Carboxymethylcellulose sodium ..... 14 mg
mannitol ..... 12 mg
poloxamer 188 ..... 4 mg
water for injection ..... 2 mL

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.

Product of Switzerland

Rx only

For Intragluteal Injection

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug appropriately.**
- **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
- After adding the diluent solution, **ensure that the powder is fully saturated** by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
- After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds** until uniform suspension is formed.

30

Sandostatin® LAR Depot
Vials are manufactured by:
Sandoz GmbH,
Schaftenau, Austria
(Subsidiary of Novartis Pharma AG,
Basel, Switzerland)
Diluent syringes are manufactured by:
Abbott Biologicals B.V.
Olst, The Netherlands
Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

300017795 US

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 30 mg
for gluteal intramuscular use

For Intragluteal Injection

47358
30 86A1

Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use

30 mg

NOVARTIS

For Intragluteal Injection

(b) (4)